Delving into the Latest Updates on Hemoporfin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

FMD, FuMeiDa, Hematoporphyrin monomethyl ether

+ [2]

Target-

Action-

Mechanism

Photosensitizers

Therapeutic Areas

Neoplasms

Active Indication

NevusNeoplasms

Inactive Indication-

Originator Organization

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Active Organization

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (29 Sep 2016),

Neoplasms

RegulationSpecial Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC35H40N4O6

InChIKeyHWEFINLVIQZVMZ-OYYVZGGRSA-N

CAS Registry148471-91-4

SummaryPort‐wine birthmarks (PWB) are common vascular malformations in infants. Despite various laser and light‐based treatments, comparative data on their effectiveness is limited. This study compares different treatments for PWB using a systematic review and network meta‐analysis (NMA). We searched for randomized controlled trials (RCTs) and ongoing studies up to November 2023: Primary outcomes were patient satisfaction, investigator‐assessed reduction in redness, and long‐term adverse events (AEs). Risk of bias was assessed using the Cochrane Risk of Bias 2 Tool.We identified 27 RCTs for qualitative analysis and twelve RCTs for the NMA, covering 1033 observations, 19 treatments, and three sub‐networks. Seven studies reported on patient satisfaction. Hemoporfin‐mediated photodynamic therapy was more effective in lesion clearance than PDL but had the highest risk of AEs. The 755 nm alexandrite laser and the combination of 595 nm PDL + 1064 nm Nd:YAG also showed high AE risks. Treatment discontinuation rates due to AEs did not significantly differ. Most studies had unclear bias risks, mostly owing to insufficient reporting.This study is the first NMA comparing laser‐ and light‐based therapies for PWB. Further well‐designed studies are warranted to determine optimal methods and patient‐influencing factors for individualized treatments.

20 Dec 2024·Chinese Medical Journal

Optical clearing agent combined with hemoporfin-mediated photodynamic therapy for improved efficacy of port-wine stain patients: A pilot study

Article

Author: Cai, Zhen ; Zhu, Jintao ; Wang, Congcong ; Zhang, Lianbin ; Wen, Jingjing ; Zhu, Jinjin ; Li, Yan ; Zhang, Yamin ; Tao, Juan

Photodynamic therapy (PDT) is an alternative treatment option for port-wine stains (PWSs) and offers several advantages over pulsed dye lasers (PDLs).However, some patients still experience treatment resistance and significant side effects.Optical clearing agent (OCA) has been shown to enhance light penetration in mouse models.Therefore, we aimed to assess whether combined OCA pretreatment can improve clin. PDT therapy outcomes and investigate the effectiveness of different types of OCA, especially hyaluronic acid microneedles (HA-MNs), in enhancing PDT.Nine patients took part in the study, including four who were resistant to PDL and three who did not respond to regular PDT.Seven patients received OCA adjuvant therapy once, while two underwent three sessions of OCA treatment.Pretreatment with OCA resulted in faster treatment attainment (mild purpura and greying), with reduced energy requirements (264.2±207.2 J/cm²) and shorter light irradiation durations (2.17±1.94 min).Pain scores significantly decreased, as shown by a decline in the mean Visual Analog Scale pain score (7.17±1.17 vs. 5.11±1.17, P<0.05).Among the OCA groups, the HA-MN group exhibited the highest therapeutic effect.The glycerol and glycerol combined with ultrasound groups also showed improvement rates of 8.05% (0.79-15.32%) and 3.26% (-5.81% to 12.33%), resp., compared to the placebo group.Notably, two patients in the HA-MN group who were previously predicted to have refractory PWS demonstrated an effective response to the third treatment.No significant differences were observed in itching and edema; blisters were reported in the HA-MN area but resolved after two weeks of selfcare.No permanent adverse events were observedThe study′s constraints include a small sample size, necessitating expanded clin. observations with a larger sample size.In conclusion, our study suggests that OCA, particularly HA-MN, can enhance PDT efficacy and reduce energy, duration, and side effects in refractory PWS treatment.Further studies with larger sample sizes are needed to confirm these findings.

01 Dec 2024·Photodiagnosis and Photodynamic Therapy

Evaluation of efficacy of Hemoporfin-PDT in the treatment of PWS birthmarks of young children previously received PDL treatment

Article

Author: Wang, Yawen ; Mu, Shengzhi ; Geng, Songmei ; Zhang, Rongrui ; Hu, Die ; Zhou, Jun ; Liu, Jing ; Qi, Chunzhi ; Zeng, Weihui ; Li, Youbao ; Wang, Zhao

BACKGROUNDHemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) is considered a safe and effective treatment for port-wine stains (PWS). This study aims to investigate the influence of prior pulse dye laser (PDL) treatments history on the effectiveness of Hemoporfin-PDT in young children aged 1-3 years with PWS.METHODSData was gathered for individuals with PWS aged 1-3 years who received two or more Hemoporfin-PDT treatments. The study population was stratified into two groups: Cohort 1 (No PDL) comprised patients without a history of PDL treatment, while Cohort 2 (Prior PDL) consisted of patients with a history of PDL treatment. An analysis was conducted to investigate the relationship between treatment efficacy and variables including gender, age, location, and type of PWS.RESULTSThere were a total of 220 cases in the No PDL group and 53 cases in the Prior PDL group. It was observed that prior PDL treatment history did not impact the efficacy of Hemoporfin-PDT in treating PWS among young children. Both the type and location of PWS significantly influence the clinical effectiveness of Hemoporfin-PDT for PWS (P = 0.040, P < 0.001), while gender and age show no association with treatment outcomes (P > 0.05). Notably, the peripheral face might be an independent influencing factor for high efficacy of Hemoporfin-PDT of the facial regions (P < 0.05).CONCLUSIONPrevious PDL treatment history does not impact the effectiveness of Hemoporfin-PDT therapy in young children with PWS.

100 Deals associated with Hemoporfin

Login to view more data